Jeffrey Eckert is an accomplished CMC leader with over 25 years of experience in pharmaceutical development and manufacturing. Currently, as the Executive Director of CMC Small Molecules at Roivant, Eckert supports drug substance process research and development for an inhalation product in clinical trials. Past leadership roles include serving as Executive Director at Sage Therapeutics, where they oversaw various aspects of early-phase pipeline development, and working at renowned companies such as Merck, Celgene, and Schering-Plough Research Institute. Eckert holds a Ph.D. in Synthetic Organic Chemistry from the Massachusetts Institute of Technology and a BS in Chemistry from Furman University.
Location
New York, United States
This person is not in the org chart
This person is not in any teams
This person is not in any offices